Sharma A et al. |
Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA. |
2014 |
Clin Drug Investig |
pmid:24214232
|
Donate-Correa J et al. |
Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease. |
2014 |
Mediators Inflamm. |
pmid:24511210
|
Carpenter TO et al. |
Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study. |
2014 |
J. Clin. Endocrinol. Metab. |
pmid:25029424
|
Coyne DW et al. |
A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. |
2014 |
Clin J Am Soc Nephrol |
pmid:24970869
|
Halder SK et al. |
Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids. |
2014 |
Reprod Sci |
pmid:24925855
|
Manucha W |
[Mitochondria and oxidative stress participation in renal inflammatory process]. |
2014 |
Medicina (B Aires) |
pmid:24918679
|
Sezer S et al. |
Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients. |
2014 |
Int J Artif Organs |
pmid:24619898
|
Ellam T et al. |
Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice. |
2014 |
PLoS ONE |
pmid:24586387
|
GarcÃa IM et al. |
Vitamin D receptor-modulated Hsp70/AT1 expression may protect the kidneys of SHRs at the structural and functional levels. |
2014 |
Cell Stress Chaperones |
pmid:24222043
|
Freundlich M et al. |
Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats. |
2014 |
Am. J. Hypertens. |
pmid:24072555
|